Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives $9.31 Average Target Price from Analysts

Trevi Therapeutics, Inc. (NASDAQ:TRVI) has received an average recommendation of “Buy” from the ten analysts that are currently covering the company, Marketbeat reports. Eight research analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $9.31.

TRVI has been the subject of a number of research analyst reports. Needham & Company LLC restated a “buy” rating and set a $8.00 price objective on shares of Trevi Therapeutics in a research report on Thursday, December 12th. Leerink Partners began coverage on Trevi Therapeutics in a report on Monday, September 9th. They issued an “outperform” rating and a $7.00 price objective on the stock. HC Wainwright increased their target price on Trevi Therapeutics from $6.00 to $7.50 and gave the company a “buy” rating in a report on Thursday, December 12th. D. Boral Capital reaffirmed a “buy” rating and issued a $21.00 price target on shares of Trevi Therapeutics in a research note on Thursday, December 12th. Finally, B. Riley reissued a “buy” rating and issued a $6.00 price objective on shares of Trevi Therapeutics in a research note on Monday, October 7th.

Trevi Therapeutics Stock Performance

TRVI stock opened at $4.59 on Thursday. The firm’s fifty day moving average is $3.31 and its 200 day moving average is $3.09. The firm has a market cap of $352.81 million, a PE ratio of -10.43 and a beta of 0.96. Trevi Therapeutics has a one year low of $1.27 and a one year high of $4.68.

Trevi Therapeutics (NASDAQ:TRVI) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01). During the same period in the prior year, the business earned ($0.08) earnings per share. Research analysts predict that Trevi Therapeutics will post -0.49 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Trevi Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the company. BNP Paribas Financial Markets raised its position in shares of Trevi Therapeutics by 130.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 11,930 shares of the company’s stock valued at $40,000 after buying an additional 6,764 shares during the period. American Century Companies Inc. increased its stake in Trevi Therapeutics by 17.1% during the second quarter. American Century Companies Inc. now owns 54,108 shares of the company’s stock worth $161,000 after acquiring an additional 7,902 shares during the last quarter. MAI Capital Management raised its position in Trevi Therapeutics by 0.7% in the third quarter. MAI Capital Management now owns 1,327,285 shares of the company’s stock valued at $4,433,000 after purchasing an additional 8,789 shares during the period. The Manufacturers Life Insurance Company lifted its stake in shares of Trevi Therapeutics by 87.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 24,524 shares of the company’s stock valued at $73,000 after purchasing an additional 11,450 shares during the last quarter. Finally, Intech Investment Management LLC acquired a new stake in shares of Trevi Therapeutics during the 3rd quarter worth about $63,000. 95.76% of the stock is currently owned by institutional investors and hedge funds.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.